Clinical Trial

Study of CM559 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 29, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT07175506
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions Healthy Subjects
Enrollment 40 participants
Start Date 2025-09
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-29